Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICG318 CAR-T in Refractory Inflammatory Myopathy
NCT07715136Phase 1Recruiting
- Sponsor
- iCell Gene Therapeutics
- Start
- Mar 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ICG318 in idiopathic inflammatory myopathy (IIM), sponsored by iCell Gene Therapeutics. Primary endpoint: Number of Adverse Events up to 2 years. Started Mar 2025; status: recruiting.
02
Drugs
ICG318
03
Conditions
idiopathic inflammatory myopathy (IIM)
Beyond the preview
Go deeper on NCT07715136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07715136.